通过荧光原位杂交对福尔马林固定石蜡包埋样品中的基因扩增进行稳健检测
July 12th, 2024
2.4K views
该方案提供了一种可重复的方法，用于可视化福尔马林固定石蜡包埋 （FFPE） 组织标本中的基因扩增。
癌基因扩增是癌症的关键驱动因素。对 FFPE 样品进行细胞遗传学表征是研究癌基因扩增的一种经济高效的方法。我们为研究局灶性基因扩增和 FFPE 样品提供了稳健而全面的说明。
通过检查 FISH 信号模式，可以明确地清楚基因位点是否以及如何被扩增。发现作为额外染色体 DNA 扩增的癌基因在人类癌症中普遍存在，例如肺癌、乳腺癌和脑癌。全基因组测序和 FISH 是检测染色体外 DNA 的最广泛使用的方法。
将 FISH 应用于 FFPE 组织具有挑战性，因为交联伪影和背景自发荧光通常会破坏数据质量。我们的方案包括优化的程序，包括蛋白质提取和消化、热变性和自发荧光淬灭技术，以提高 FFPE 样本 FISH 期间的数据质量，这将为患者的癌症进展提供有价值的见解。我们将研究染色体外 DNA 的分子功能，以及癌细胞如何维持染色体外 DNA。
最终，我们的目标是消除它们来治疗癌症。
概述
该协议提供了一种可重复的方法，用于在甲醛固定石蜡包埋（FFPE）组织标本中可视化基因扩增。通过利用FISH技术，研究人员可以有效地研究癌基因扩增，这是癌症进展的重要因素。
关键研究组成部分
科学领域
- 肿瘤学
- 遗传学
- 细胞遗传学
背景
- 癌基因扩增是癌症的关键驱动因素。
- FFPE样本常用于细胞遗传学特征分析。
- FISH技术对于检测基因扩增至关重要。
- 挑战包括FFPE组织中的交联伪影和自体荧光。
研究目的
- 提供FFPE样本FISH分析的优化程序。
- 研究癌细胞中染色体外DNA的分子功能。
- 改善数据质量并深入了解癌症进展。
使用的方法
- FFPE切片的样本制备和预处理。
- 使用蛋白酶K进行蛋白质提取和消化。
- FISH杂交和成像技术。
- 使用最大3D投影和去卷积算法进行数据分析。
主要结果
- 在三阴性乳腺癌样本中观察到不同的FISH信号模式。
- HER2阳性样本表现出丰富的FISH信号，表明基因扩增。
- 在一些细胞核中发现了染色体外DNA集群。
- 优化的方法提高了FFPE组织FISH数据的质量。
结论
- 该协议增强了研究癌症中癌基因扩增的能力。
- 改进的技术可以更好地理解癌症机制。
- 未来的研究可能会专注于消除染色体外DNA来治疗癌症。
常见问题
基因扩增在癌症中的意义是什么？
基因扩增是癌症的关键驱动因素，导致癌基因表达增加。
为什么在这项研究中使用FFPE样本？
FFPE样本在临床环境中广泛使用，因为它们能够保存组织形态和遗传物质。
在FFPE样本上进行FISH分析时会遇到哪些挑战？
挑战包括交联伪影和背景自体荧光，这些可能会影响数据质量。
该协议如何改善数据质量？
该协议包括蛋白质提取、消化和自体荧光淬灭的优化程序。
这项研究的预期结果是什么？
该研究旨在通过研究染色体外DNA，提供对癌症进展和潜在治疗靶点的见解。
Executive Industry Relevance
Robust detection of gene amplification in FFPE samples using FISH addresses a critical need for reliable oncogene assessment in archived clinical specimens. This capability enhances predictive confidence in target validation and supports risk-adjusted decisions at key discovery and translational inflection points. Standardized FISH workflows in FFPE tissues enable consistent evaluation of gene amplification, directly impacting oncology portfolio prioritization.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct visualization of gene amplification events in clinically relevant tissue contexts.
- Supports functional target validation by confirming oncogene amplification status in tumor samples.
- Facilitates mechanistic de-risking by distinguishing ecDNA-driven amplification from chromosomal events.
- Improves predictive confidence for downstream therapeutic hypothesis testing.
Screening & Assay Development
- Provides a standardized cytogenetic assay for quantifying gene amplification in FFPE samples.
- Ensures reproducibility and comparability of results across diverse tissue archives.
- Delivers quantitative imaging outputs suitable for assay benchmarking and platform validation.
- Enables reliable screening of candidate biomarkers in oncology research pipelines.
Translational & Preclinical Research
- Aligns gene amplification detection with disease-relevant tissue models for translational continuity.
- Supports biomarker-driven patient stratification in preclinical studies.
- Facilitates risk-adjusted advancement of oncology assets based on validated amplification status.
- Provides mechanistic insight into therapy resistance linked to ecDNA in cancer progression.
Pipeline & Workflow Integration
This FISH protocol integrates into the discovery-to-translational continuum by enabling robust gene amplification assessment in FFPE samples, bridging early discovery, assay development, and translational research workflows.
- Discovery Biology: Supports hypothesis testing and pathway clarification by confirming oncogene amplification in archived tissues.
- Screening: Delivers reproducible, quantitative FISH readouts for assay standardization and compound evaluation.
- Analytics: Provides high-resolution imaging and quantitative signal analysis for comparative studies.
- Translational Research: Ensures continuity of biomarker validation from discovery through preclinical models using clinically relevant samples.
- Enterprise Reuse: Establishes a reusable, standardized workflow for gene amplification detection across oncology programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Enhances standardization, reproducibility, and scalability of gene amplification assays in FFPE tissues.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by enabling robust biomarker assessment.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of oncology assets based on validated amplification data.
Implementation Considerations
- Requires expertise in cytogenetics and fluorescence imaging for optimal data acquisition.
- Demands access to high-quality imaging platforms and analytical software for signal quantification.
- Necessitates cross-team standardization of sample preparation and imaging protocols.
- May require adaptation for different tissue types or oncogene targets based on sample characteristics.
- Potential limitations include autofluorescence and cross-linking artifacts inherent to FFPE samples.
Biopharma FAQs
Why is null hypothesis testing critical for FISH-based gene amplification validation?
Null hypothesis testing in FISH-based workflows ensures that observed gene amplification patterns are statistically significant and not due to background signal or technical artifacts, supporting robust target validation decisions in oncology discovery pipelines.
How does independent variable isolation improve FFPE FISH assay reliability?
Isolating variables such as protein digestion and autofluorescence quenching in the protocol allows teams to attribute signal changes specifically to gene amplification, increasing assay reliability and interpretability for discovery and translational research.
What do quantitative FISH signal measurements enable in oncology R&D?
Quantitative FISH measurements provide objective data on gene amplification levels, enabling comparative analysis across samples and supporting data-driven decisions for biomarker validation and candidate prioritization.
Why are replication requirements important for cross-functional FISH assay deployment?
Replication ensures that FISH assay results are reproducible across different operators and laboratories, facilitating cross-functional collaboration and consistent data interpretation in multi-site oncology programs.
What statistical analysis capabilities are needed before implementing FISH in FFPE workflows?
Robust statistical analysis is required to distinguish true gene amplification from background noise, set quantitative thresholds, and validate assay performance prior to broader implementation in discovery and translational pipelines.
